Magnetic graphene oxide nanosheets with amidoamine dendronized crosslinks for dual pH and redox-sensitive doxorubicin delivery
- PMID: 39342347
- PMCID: PMC11439217
- DOI: 10.1186/s13065-024-01301-4
Magnetic graphene oxide nanosheets with amidoamine dendronized crosslinks for dual pH and redox-sensitive doxorubicin delivery
Abstract
Delivering anticancer drugs to the appropriate site within the body poses a critical challenge in cancer treatment with chemotherapeutic agents like doxorubicin (DOX). Magnetic graphene oxide (GO) nanosheets with generation 1 (G1) amidoamine-dendronized crosslinks were developed by coupling cystamine-functionalized GO nanosheets with Fe3O4 nanoparticles modified with primary amine and methyl acrylate. These magnetic GO nanosheets were loaded with DOX to create a dual pH- and redox-responsive delivery system for cancer chemotherapy. The prepared magnetic nanosheets underwent characterization using FTIR, XRD, DLS, VSM, FE-SEM, and TEM. Physical DOX adsorption was evaluated using various isotherms, including Langmuir, Freundlich, Temkin, and Dubinin-Radushkevich. The in-vitro release profiles of DOX from the magnetic nanosheets were studied under different pH conditions, with and without glutathione (GSH), and the drug release data were fitted with various kinetic models. Additionally, an MTT assay was employed to assess the compatibility and antitumor activity of DOX-loaded magnetic nanosheets in the HepG2 cell line. The results showed that the maximum drug loading was 13.1% (w/w) at a drug/carrier ratio of 1. Without GSH addition, the maximum drug release after 10 days was only 17.9% and 24.1% at pH 7.4 and 5.3, respectively. However, in the presence of GSH, the maximum drug release reached 51.7% and 64.8% at pH 7.4 and 5.3, respectively. Finally, the research findings suggest that the magnetic nanosheets exhibited pH- and redox-stimuli drug release, high biocompatibility, and superior antitumor activity compared to free DOX.
Keywords: Doxorubicin; Drug release kinetic; Fe3O4; Graphene oxide; Redox; Stimuli-responsive; Superparamagnetic nanoparticle.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures









References
-
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. - PubMed
-
- Arabestanino AR, Naghibi Irvani SS, Ai A, Dinarvand B. Structural carcinoma overall process: a systematic review. Cell Mol Biomedical Rep. 2024;4(2):88–99.
-
- Ali Salman R. Prevalence of women breast cancer. Cell Mol Biomedical Rep. 2023;3(4):185–96.
-
- Li X, Li D. Natural compounds targeting cellular redox homeostasis in malignancies. Cell Mol Biol (Noisy-le-grand). 2023;69(14):255–65. - PubMed
-
- Eralp TN, Sevinc A, Mansuroglu B. Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231. Cell Mol Biol (Noisy-le-grand). 2024;70(2):169–77. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources